Francesco Tovoli
AuthID: R-00K-HMT
1
TÃTULO: Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population Full Text
AUTORES: Casadei Gardini, Andrea; Rimini, Margherita; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Rimassa, Lorenza; Presa, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Tovoli, Francesco; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; ...Mais
PUBLICAÇÃO: 2023, FONTE: EUROPEAN JOURNAL OF CANCER, VOLUME: 180
AUTORES: Casadei Gardini, Andrea; Rimini, Margherita; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Rimassa, Lorenza; Presa, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Tovoli, Francesco; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; ...Mais
PUBLICAÇÃO: 2023, FONTE: EUROPEAN JOURNAL OF CANCER, VOLUME: 180
INDEXADO EM: Scopus WOS
2
TÃTULO: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients Full Text
AUTORES: Persano, Mara; Rimini, Margherita; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Presa, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Tovoli, Francesco; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; Himmelsbach, Vera; ...Mais
PUBLICAÇÃO: 2023, FONTE: EUROPEAN JOURNAL OF CANCER, VOLUME: 189
AUTORES: Persano, Mara; Rimini, Margherita; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Presa, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Tovoli, Francesco; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; Himmelsbach, Vera; ...Mais
PUBLICAÇÃO: 2023, FONTE: EUROPEAN JOURNAL OF CANCER, VOLUME: 189
INDEXADO EM: Scopus WOS
3
TÃTULO: Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large, real-life, worldwide population.
AUTORES: Rimini, Margherita; Casadei Gardini, Andrea; Persano, Mara; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Rimassa, Lorenza; Presa, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Tovoli, Francesco; Scartozzi, Mario; Burgio, Valentina; Cascinu, Stefano; Cucchetti, Alessandro;
PUBLICAÇÃO: 2023, FONTE: Genitourinary Cancers Symposium in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 41
AUTORES: Rimini, Margherita; Casadei Gardini, Andrea; Persano, Mara; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Rimassa, Lorenza; Presa, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Tovoli, Francesco; Scartozzi, Mario; Burgio, Valentina; Cascinu, Stefano; Cucchetti, Alessandro;
PUBLICAÇÃO: 2023, FONTE: Genitourinary Cancers Symposium in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 41
INDEXADO EM: WOS
4
TÃTULO: Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study Full Text
AUTORES: Persano, Mara; Rimini, Margherita; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Rimassa, Lorenza; Presa, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Tovoli, Francesco; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; ...Mais
PUBLICAÇÃO: 2022, FONTE: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
AUTORES: Persano, Mara; Rimini, Margherita; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Rimassa, Lorenza; Presa, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Tovoli, Francesco; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; ...Mais
PUBLICAÇÃO: 2022, FONTE: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
INDEXADO EM: Scopus WOS